On November 13, 2017, the U.S. Food and Drug Administration (FDA) approved Abilify MyCite (aripiprazole tablets with sensor), the first pill to include a digital sensor that tracks if and when it has been ingested. Abilify, and its generic version, aripriprazole, are used to treat schizophrenia, bipolar disorder and – in combination with other medications – major depressive disorder.
We are experiencing a revolution in healthcare, with powerful medicine and innovative technology coming together to transform the way we treat patients and manage diseases. While there are ethical considerations to address, the promise of digital health is undeniable.
Speak With Our Experts